Abstract

Background: Parkinson’s disease is a chronic progressive disease of the nervous system characterized by the cardinal features of rigidity, bradykinesia, tremor and postural instability. In Parkinson’s disease every year there are less than 10 new cases per 100000 under age of 50. while there are at least 300 new cases per 100000 ages 80 to 99 years annually. Pulmonary complications associated with Parkinson’s diseases a common reason for hospital admission 35.8% reported shortness of breath on exertion, 17.9% reported cough, 13% reported sputum production. Pulmonary function test is mainly used to check the lung function capacity in Parkinson’s patients. In Parkinson’s patients due to forward head stoop posture there is decrease in lung function capacity. In Parkinson’s disease morbidity and mortality are commonly caused by respiratory disorders from pulmonary function impairments. Aims: The study aim is to find out pulmonary function capacity in Parkinson’s disorder patients. Objective: (1) To check FVC in Parkinson’s disorder patients. (2) To check FEV1 in Parkinson’s disorder patients. (3) To check FEV1/FVC ratio in Parkinson’s disorder patients. Method: Pulmonary function test was conducted using PFT software and PFT probe (HELIOS-401) and results of FVC, FEV1, FEV1/FVC ratio were obtained from Parkinson’s disease patients. Result: The data was assessed using PFT; the study showed that there has been a significant reduction in lung function capacity of the Parkinson’s disorder patients. Conclusion: In the present study we concluded that the lung function capacity of Parkinson’s disorder patients was very low compared to that of normal individuals.

• 1.   Adams RD, Victor M, Ropper AH (1997). Abnormalities ofmovements and posture due to disease of the basal ganglia.In: Principles of Neurology, 6th edn. McGraw-Hill, NewYork, pp. 64±83.
• 2.   Bogaard JM, Hovestadt A, Meerwaldt J, Meche FGA, Stigt J(1989). Maximal expiratory and inspiratory ¯ow±volumecurves in Parkinson’s disease. Am Rev Respir Dis 139:610±614.
• 3.   Fontana GA, Pantaleo T, Lavorini F, Benvenuti F, GangemiS (1998). Defective motor control of coughing inParkinson’s disease. Am J Respir Crit Care Med158:458±464.
• 4.   Gold WM (2000). Pulmonary function testing. In: Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. W.B.Saunders Co., Philadelphia, pp. 781±881.
• 5.   Gorell JM, Johnson CC, Rybicki BA (1994). Parkinson’sdisease and its comorbid disorders: an analysis of Michiganmortality data, 1970 ±1990. Neurology 44:1865±1868.
• 6.   Hoehn MM, Yahr MD (1967). Parkinsonism: onset, progression and mortality. Neurology 17:427±442.
• 7.   Irwin RS, Boulet LP, Cloutier MM et al. (1998). Managingcough as a defence mechanism and as a symptom. Aconsensus panel report of the American College of ChestPhysicians. Chest 114:133s±142s.
• 8.   Kakinuma S, Nogaki H, Pramanik B, Morimatsu M (1998). Muscle weakness in Parkinson’s disease: isokinetic study ofthe lower limbs. EurNeurol 39:218±222.
• 9.   Koseoglu F, Inan L, Ozel S et al. (1997). The effects of apulmonary rehabilitation program on pulmonary functiontests and exercise tolerance in patients with Parkinson’sdisease. ctNeurol 12:319±325.

Data Sharing Statement

Funding